Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

ECTRIMS 2016: Biogen Makes Headway in MS Remyelination Studies

Executive Summary

Biogen has identified the type of MS patient likely to respond to its remyelination approach with the investigational MAb opicinumab, even though its Phase II SYNERGY trial missed its primary endpoint.


Related Content

Neuroscience Reaches A New Inflection Point, Big Biotechs Say
GeNeuro’s Causal Approach To MS Treatment Gathers Momentum
Biogen Anti-LINGO MS Study Failure Removes Upside


Related Companies